Using a combination of drugs to treat Alzheimer's disease through aging processes
A geroscience approach for treating Alzheimer's disease
This study is exploring a new way to treat Alzheimer's by using a mix of three existing medications that might help slow down aging, and it's looking for patients to join the trials to see how safe and effective this treatment can be.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10810775 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating Alzheimer's disease by focusing on the biological processes of aging. It aims to use a combination of three repurposed drugs—phenylbutyrate, rapamycin, and acarbose—that have shown potential anti-aging effects in previous studies. By targeting multiple mechanisms involved in aging and Alzheimer's, the research seeks to develop a more effective treatment strategy. Patients may be involved in trials to assess the safety and efficacy of this drug cocktail.
Who could benefit from this research
Good fit: Ideal candidates for participation are older adults diagnosed with Alzheimer's disease or those at risk of developing it.
Not a fit: Patients with early-stage Alzheimer's or those with other forms of dementia unrelated to aging may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that slows the progression of Alzheimer's disease and improves the quality of life for patients.
How similar studies have performed: Previous research has shown promise in using multi-targeted approaches for age-related diseases, suggesting potential for success in this novel application.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Ladiges, Warren C — University of Washington
- Study coordinator: Ladiges, Warren C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.